MedTrace Logo

Impacts of Nicotinamide Riboside on Functional Capacity and Muscle Physiology in Older Veterans

NCT04691986 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 74

Last updated 2026-04-29

No results posted yet for this study

Summary

Frailty is an age-associated clinical condition of poor physiological reserve that increases risks for falls, hospitalization and mortality. Nicotinamide adenine dinucleotide (NAD) is a critical co-factor needed for many cellular processes. The natural levels of NAD decline aging and this has been linked to physical performance decline in animals. Human trials have demonstrated that nicotinamide riboside (NR), a form of vitamin B3, is safe and effectively increases NAD+ levels. In animal studies, NR improves treadmill performance and muscle quality. Here the investigators propose a double-blind randomized control trial to assess the benefits of NR supplementation on human muscle function and physiology. The investigators anticipate the research findings will support the use of this nutritional supplement to improve the health of Veterans during aging.

Conditions

  • Sarcopenia
  • Nicotinamide Adenine Dinucleotide Concentration
  • Muscle Quality and NAD+ Content

Interventions

DIETARY_SUPPLEMENT

Nicotinamide Riboside

Nicotinamide Riboside is a form of vitamin B3 and is naturally occurring in humans.

OTHER

Placebo

Placebo pills contain micro cellulose powder.

Sponsors & Collaborators

  • University at Buffalo

    collaborator OTHER

  • VA Office of Research and Development

    lead FED

Principal Investigators

  • Kenneth L Seldeen, PhD · Kansas City VA Medical Center, Kansas City, MO

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
65 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-09-01
Primary Completion
2026-03-31
Completion
2026-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04691986 on ClinicalTrials.gov